LT4801B - Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija - Google Patents

Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija Download PDF

Info

Publication number
LT4801B
LT4801B LT1999114A LT99114A LT4801B LT 4801 B LT4801 B LT 4801B LT 1999114 A LT1999114 A LT 1999114A LT 99114 A LT99114 A LT 99114A LT 4801 B LT4801 B LT 4801B
Authority
LT
Lithuania
Prior art keywords
apo
phytosterols
composition
disease
cholesterol
Prior art date
Application number
LT1999114A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT99114A (lt
Inventor
Egon Novak
Original Assignee
Forbes Medi-Tech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi-Tech Inc. filed Critical Forbes Medi-Tech Inc.
Publication of LT99114A publication Critical patent/LT99114A/xx
Publication of LT4801B publication Critical patent/LT4801B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LT1999114A 1997-12-18 1999-09-16 Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija LT4801B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/993,901 US5985936A (en) 1997-12-18 1997-12-18 Method of preventing and delaying onset of Alzheimer's disease and composition therefor

Publications (2)

Publication Number Publication Date
LT99114A LT99114A (lt) 2001-01-25
LT4801B true LT4801B (lt) 2001-06-25

Family

ID=25540052

Family Applications (1)

Application Number Title Priority Date Filing Date
LT1999114A LT4801B (lt) 1997-12-18 1999-09-16 Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija

Country Status (18)

Country Link
US (1) US5985936A (bg)
EP (1) EP0967982A2 (bg)
CN (1) CN1252724A (bg)
AU (1) AU1656099A (bg)
BG (1) BG103740A (bg)
BR (1) BR9807577A (bg)
CA (1) CA2281710A1 (bg)
EE (1) EE9900354A (bg)
GE (1) GEP20022783B (bg)
HU (1) HUP0100737A3 (bg)
LT (1) LT4801B (bg)
LV (1) LV12438B (bg)
MD (1) MD1920F2 (bg)
NO (1) NO993979L (bg)
PL (1) PL335421A1 (bg)
RU (1) RU2173151C2 (bg)
SK (1) SK112999A3 (bg)
WO (1) WO1999032097A2 (bg)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
EP1225880A2 (en) * 1999-11-04 2002-07-31 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
BR0110084A (pt) 2000-04-14 2002-12-31 Mars Inc Composições e métodos para melhorar saúde vascular
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
DE60224078T2 (de) * 2001-02-12 2008-12-04 N.V. Organon Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind.
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CA2517573C (en) * 2003-03-07 2011-12-06 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20050277129A1 (en) * 2004-01-22 2005-12-15 Genaissance Pharmaceuticals APOE genetic markers associated with age of onset of Alzheimer's disease
US7704955B2 (en) * 2004-11-24 2010-04-27 Neopro Pain, Inc. Methods and compositions for modulating conditions in both mammals and plants
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
CN101977606A (zh) * 2008-03-27 2011-02-16 伊沃泰克神经科学有限责任公司 使用nmda nr2b亚型选择性拮抗剂来治疗病症的方法
WO2010104375A1 (en) * 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10307450B2 (en) 2010-01-11 2019-06-04 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
US9376481B2 (en) 2011-04-26 2016-06-28 The Regents Of The University Of California Methods of promoting CNS neuronal repair by inhibiting LRP-1
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2015123618A1 (en) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Method for increasing bcl2 gene expression
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
CN111417384A (zh) 2017-09-14 2020-07-14 菲尼克斯生物技术公司 用于治疗神经系统病况的方法和改进的神经保护性组合物
US11331291B2 (en) 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
EP4081198A1 (en) 2019-12-24 2022-11-02 Folium Biosciences Europe B.V. Food supplement for alzheimer
EP3842039A1 (en) * 2019-12-24 2021-06-30 Folium Biosciences Europe B.V. Food supplement comprising cannbinoids and phytosterols for alzheimer
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
AU6274394A (en) * 1993-02-23 1994-09-14 Pharmakon Usa, Inc. Therapeutic herbal composition
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
NZ293210A (en) * 1994-09-29 2000-03-27 Univ British Columbia A process for purifying and preparing phytosterol composition derived from a pulping soap
CN1179903A (zh) * 1996-10-09 1998-04-29 李辉 营养丝米粉
JP4386470B2 (ja) * 1997-05-15 2009-12-16 ユニバーシティ・オブ・ワシントン アルツハイマー病および他のアミロイド症のための組成物および方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOYLES ET AL.: "A role for apoliprotein-E, apoliprotein A-I and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of tjr rat sciatic nerve", J. CLIN. INVEST., 1989, pages 1015 - 1031
ELSHOURBAGY ET AL.: "Apoliprotein E mRNA is abundant in the brain and adreals as well as in liver and is present in other peripheral tissues in rats and marmosets", PROC. NATI. ACAD. SCI. USA, 1985, pages 203 - 207
HANDELMANN ET AL.: "Effects of apolipoprotein E, Beta-very low density lipoproteins and cholesterol on the extension of neurits by rabit dorsal root ganglion neurons in vivo", J. LIPID RES., 1992, pages 1677 - 1688
MULLER M. ET AL.: "A specific 37.000-dalton protein that accumulates in regerating but non-regenerating mammalian", SCIENCE, 1985, pages 499 - 501
STRITTMATTER ET AL.: "Hypothesis: microtubule instability and paired helical filament formation in the Alzheimers desease brain are related to apolipoprotein-E genotype", EXP. NEUROL., 1994, pages 163 - 171
STRITTMATTER ET AL.: "Isoform specific interactions for Alzheimers desease", PROC NATL ACAD SCI U S A., 1994, pages 11183 - 11186

Also Published As

Publication number Publication date
HUP0100737A2 (hu) 2001-09-28
CA2281710A1 (en) 1999-07-01
NO993979D0 (no) 1999-08-18
LT99114A (lt) 2001-01-25
RU2173151C2 (ru) 2001-09-10
EE9900354A (et) 2000-02-15
WO1999032097A3 (en) 1999-09-02
NO993979L (no) 1999-10-13
SK112999A3 (en) 2001-11-06
LV12438A (en) 2000-03-20
PL335421A1 (en) 2000-04-25
BR9807577A (pt) 2001-08-07
GEP20022783B (en) 2002-09-25
CN1252724A (zh) 2000-05-10
HUP0100737A3 (en) 2002-07-29
WO1999032097A2 (en) 1999-07-01
LV12438B (en) 2000-09-20
US5985936A (en) 1999-11-16
EP0967982A2 (en) 2000-01-05
MD990262A (en) 2000-06-30
BG103740A (bg) 2000-05-31
MD1920F2 (ro) 2002-05-31
AU1656099A (en) 1999-07-12

Similar Documents

Publication Publication Date Title
LT4801B (lt) Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija
Kariv-Inbal et al. The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol
Chernick et al. Peripheral versus central nervous system APOE in Alzheimer’s disease: Interplay across the blood-brain barrier
Troutwine et al. Apolipoprotein E and Alzheimer's disease
Salem Jr et al. The benefit of docosahexaenoic acid for the adult brain in aging and dementia
Martins et al. Cholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease
Leduc et al. APOE and cholesterol homeostasis in Alzheimer's disease
Vance et al. Cholesterol homeostasis in neurons and glial cells
Yu et al. The alteration of autophagy and apoptosis in the hippocampus of rats with natural aging-dependent cognitive deficits
Karten et al. Mechanisms and consequences of impaired lipid trafficking in Niemann–Pick type C1-deficient mammalian cells
Stein et al. Lipid transfer proteins (LTP) and atherosclerosis
Maria Giudetti et al. The role of brain cholesterol and its oxidized products in Alzheimer's disease
Teter ApoE-dependent plasticity in Alzheimer’s disease
Montine et al. Central nervous system lipoproteins in Alzheimer's disease.
JP2004505910A (ja) アポリポタンパク質ｅ分泌を誘導するための方法
Turri et al. Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders
Takechi et al. Chylomicron amyloid-beta in the aetiology of Alzheimer's disease
Berbée et al. Apolipoprotein CI knock-out mice display impaired memory functions
Dragan et al. Can we change the functionality of HDL cholesterol with nonpharmacological and pharmacological agents?
JP2013520444A (ja) 高コレステロール血症を処置するための薬剤及び機序
Levi et al. Regulation of hippocampal cholesterol metabolism by apoE and environmental stimulation
Blain et al. Cholesterol homeostasis and the pathophysiology of Alzheimer’s disease
Xu et al. Lipid metabolism in Alzheimer's and Parkinson's disease
Hone et al. Fat and lipid metabolism and the involvement of apolipoprotein E in Alzheimer's disease
MXPA99007622A (en) Method of preventing and delaying the onset of alzheimer's disease and composition therefor

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20021218